Study cohort
. | Patient . | Origin . | Demographic data . | Clinical data . | Analysis . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sex . | Age (y) . | HL subtype . | HIV status . | HIV treatment . | EBV status . | Log10VL (copies per mL) at HL diagnosis . | CD4 T cells (cells per mm3) at HIV diagnosis . | CD4 T cells (cells per mm3) at HL diagnosis . | CD4 T cells (cells per mm3) currently . | ||||
HLposHIVnegEBVneg | 1 | Switzerland | M | 33 | LRHL | Negative | No | Negative by ISH | Imaging/HTG | ||||
2 | Switzerland | M | 21 | NSHL | Negative | No | Negative by ISH | Imaging/HTG | |||||
3 | Switzerland | F | 21 | NSHL | Negative | No | Negative by ISH | Imaging/HTG | |||||
4 | Switzerland | F | 73 | MCHL | Negative | No | Negative by ISH | Imaging/HTG/GeoMx | |||||
5 | Switzerland | F | 30 | NSHL | Negative | No | Negative by ISH | Imaging/HTG | |||||
6 | Switzerland | M | 75 | MCHL | Negative | No | Negative by ISH | Imaging/GeoMx | |||||
7 | Switzerland | M | 44 | NSHL | Negative | No | Negative by ISH | Imaging | |||||
8 | Switzerland | M | 32 | NSHL | Negative | No | Negative by ISH | Imaging | |||||
HLposHIVnegEBVpos | 9 | Switzerland | M | 78 | MCHL | Negative | No | Positive by ISH | Imaging/HTG | ||||
10 | Switzerland | F | 76 | MCHL | Negative | No | Positive by ISH | Imaging/HTG/GeoMx | |||||
11 | Switzerland | M | 64 | MCHL | Negative | No | Positive by ISH | Imaging/HTG/GeoMx | |||||
12 | Switzerland | M | 36 | MCHL | Negative | No | Positive by ISH | Imaging/HTG/GeoMx | |||||
13 | Switzerland | F | 78 | NSHL | Negative | No | Positive by ISH | Imaging/HTG | |||||
14 | Switzerland | M | 50 | NSHL | Negative | No | Positive by ISH | Imaging/HTG | |||||
15 | Switzerland | M | 34 | NSHL | Negative | No | Positive by ISH | Imaging/HTG | |||||
16 | Switzerland | M | 78 | MCHL | Negative | No | Positive by ISH | Imaging/HTG/GeoMx | |||||
17 | Switzerland | M | 43 | NSHL | Negative | No | Positive by ISH | Imaging | |||||
18 | Switzerland | M | 54 | MCHL | Negative | No | Positive by ISH | Imaging | |||||
19 | Switzerland | F | 60 | cHL | Negative | No | Positive by ISH | Imaging | |||||
20 | Switzerland | M | 60 | NSHL | Negative | No | Positive by ISH | Imaging | |||||
HLposHIVposEBVpos | 21 (+ART) | Switzerland | M | 59 | NSHL | Positive | Yes | Positive by ISH | 4.95 | 532 | NA | NA | Imaging/HTG |
22 (+ART) | Switzerland | F | 32 | NSHL | Positive | Yes | Positive by ISH | <1.3 | NA | NA | 1227 | Imaging/HTG | |
23 (+ART) | Greece | M | 43 | MCHL | Positive | Yes | Positive by ISH | <1.6 | 928 | 717 | 1820 | Imaging/HTG/GeoMx | |
24 | Greece | M | 34 | MCHL | Positive | No | Positive by ISH | 4.96 | 340 | 327 | 680 | Imaging/HTG/GeoMx | |
25 (+ART) | Greece | M | 37 | MCHL | Positive | Yes | Positive by ISH | <1.3 | 963 | 341 | 776 | Imaging/HTG/GeoMx | |
26 | Greece | F | 26 | LDHL | Positive | No | Positive by ISH | 4.79 | 410 | 410 | NA | Imaging/HTG | |
27 | Greece | M | 52 | LDHL | Positive | No | Positive by ISH | 4.85 | 555 | 265 | 526 | Imaging/HTG | |
28 (+ART) | Greece | M | 54 | MCHL | Positive | Yes | Positive by ISH | 2.64 | 298 | 259 | 252 | Imaging/HTG/GeoMx | |
29 (+ART) | Greece | M | 44 | NSHL | Positive | Yes | Positive by ISH | 4.74 | 928 | 717 | 1820 | Imaging/HTG |
. | Patient . | Origin . | Demographic data . | Clinical data . | Analysis . | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sex . | Age (y) . | HL subtype . | HIV status . | HIV treatment . | EBV status . | Log10VL (copies per mL) at HL diagnosis . | CD4 T cells (cells per mm3) at HIV diagnosis . | CD4 T cells (cells per mm3) at HL diagnosis . | CD4 T cells (cells per mm3) currently . | ||||
HLposHIVnegEBVneg | 1 | Switzerland | M | 33 | LRHL | Negative | No | Negative by ISH | Imaging/HTG | ||||
2 | Switzerland | M | 21 | NSHL | Negative | No | Negative by ISH | Imaging/HTG | |||||
3 | Switzerland | F | 21 | NSHL | Negative | No | Negative by ISH | Imaging/HTG | |||||
4 | Switzerland | F | 73 | MCHL | Negative | No | Negative by ISH | Imaging/HTG/GeoMx | |||||
5 | Switzerland | F | 30 | NSHL | Negative | No | Negative by ISH | Imaging/HTG | |||||
6 | Switzerland | M | 75 | MCHL | Negative | No | Negative by ISH | Imaging/GeoMx | |||||
7 | Switzerland | M | 44 | NSHL | Negative | No | Negative by ISH | Imaging | |||||
8 | Switzerland | M | 32 | NSHL | Negative | No | Negative by ISH | Imaging | |||||
HLposHIVnegEBVpos | 9 | Switzerland | M | 78 | MCHL | Negative | No | Positive by ISH | Imaging/HTG | ||||
10 | Switzerland | F | 76 | MCHL | Negative | No | Positive by ISH | Imaging/HTG/GeoMx | |||||
11 | Switzerland | M | 64 | MCHL | Negative | No | Positive by ISH | Imaging/HTG/GeoMx | |||||
12 | Switzerland | M | 36 | MCHL | Negative | No | Positive by ISH | Imaging/HTG/GeoMx | |||||
13 | Switzerland | F | 78 | NSHL | Negative | No | Positive by ISH | Imaging/HTG | |||||
14 | Switzerland | M | 50 | NSHL | Negative | No | Positive by ISH | Imaging/HTG | |||||
15 | Switzerland | M | 34 | NSHL | Negative | No | Positive by ISH | Imaging/HTG | |||||
16 | Switzerland | M | 78 | MCHL | Negative | No | Positive by ISH | Imaging/HTG/GeoMx | |||||
17 | Switzerland | M | 43 | NSHL | Negative | No | Positive by ISH | Imaging | |||||
18 | Switzerland | M | 54 | MCHL | Negative | No | Positive by ISH | Imaging | |||||
19 | Switzerland | F | 60 | cHL | Negative | No | Positive by ISH | Imaging | |||||
20 | Switzerland | M | 60 | NSHL | Negative | No | Positive by ISH | Imaging | |||||
HLposHIVposEBVpos | 21 (+ART) | Switzerland | M | 59 | NSHL | Positive | Yes | Positive by ISH | 4.95 | 532 | NA | NA | Imaging/HTG |
22 (+ART) | Switzerland | F | 32 | NSHL | Positive | Yes | Positive by ISH | <1.3 | NA | NA | 1227 | Imaging/HTG | |
23 (+ART) | Greece | M | 43 | MCHL | Positive | Yes | Positive by ISH | <1.6 | 928 | 717 | 1820 | Imaging/HTG/GeoMx | |
24 | Greece | M | 34 | MCHL | Positive | No | Positive by ISH | 4.96 | 340 | 327 | 680 | Imaging/HTG/GeoMx | |
25 (+ART) | Greece | M | 37 | MCHL | Positive | Yes | Positive by ISH | <1.3 | 963 | 341 | 776 | Imaging/HTG/GeoMx | |
26 | Greece | F | 26 | LDHL | Positive | No | Positive by ISH | 4.79 | 410 | 410 | NA | Imaging/HTG | |
27 | Greece | M | 52 | LDHL | Positive | No | Positive by ISH | 4.85 | 555 | 265 | 526 | Imaging/HTG | |
28 (+ART) | Greece | M | 54 | MCHL | Positive | Yes | Positive by ISH | 2.64 | 298 | 259 | 252 | Imaging/HTG/GeoMx | |
29 (+ART) | Greece | M | 44 | NSHL | Positive | Yes | Positive by ISH | 4.74 | 928 | 717 | 1820 | Imaging/HTG |
cHL, classic Hodgkin Lymphoma; NSHL, Nodular Sclerosing HL; MCHL, Mixed Cellularity HL; LDHL, Lymphocyte Depleted HL; LRHL, Lymphocyte Rich HL.